Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication

Study Title
Study to Assess the Safety and Pharmacokinetics of ADASUVEֲ® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Teva Identifier
TV571-CNS-10018
ClinicalTrials.gov Identifier
NCT02184767
Study Status
Completed
Trial Condition(s)
BiPolar
Interventions
Drug: ADASUVEֲ®

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
10 Years to 17 Years
Trial Duration
07/01/2014 - 05/01/2015
Phase
Phase 1

Study Type

Interventional